Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
O03 - NSCLC - Targeted Therapies I
- Type: Oral Abstract Session
- Track: Medical Oncology
- Presentations: 8
- Moderators:J. Ross
- Coordinates: 10/28/2013, 10:30 - 12:00, Bayside Auditorium B, Level 1
-
+
O03.05 - Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three trials of afatinib in EGFR mutation-positive lung cancer
11:15 - 11:25 | Author(s): J.C. Yang
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO07 - NSCLC - Targeted Therapies II
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 14
- Moderators:T. John
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO07.13 - Efficacy of afatinib vs. chemotherapy in treatment-naïve patients with non-small cell lung cancer (NSCLC) harbouring activating EGFR mutations with or without metastatic brain disease
17:25 - 17:30 | Author(s): M. Schuler
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P2.11 - Poster Session 2 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 46
- Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P2.11-045 - TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation.
09:30 - 09:30 | Author(s): L. Nogova
- Abstract
Loading...
-
+
P3.11 - Poster Session 3 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 52
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.11-023 - Comparative safety profile of afatinib in Asian and non-Asian patients with EGFR mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): L.V. Sequist
- Abstract
Loading...